AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14516802
Drug: Atropine treatment
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine treatment
Trial: 8942345
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 2 mg h‐1 (n = 12)
Trial: 8942345
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 1 mg h‐1 (n = 12)
Trial: 22705118
Drug: Biweekly combination
RxNorm normalized name: Biweekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly combination therapy with gemcitabine (1000 mg/m²) and carboplatin (AUC 3) on days 1 and 15, every 4 weeks
Trial: 22705118
Drug: Gemcitabine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine monotherapy (1000 mg/m²) on days 1, 8, and 15, every 4 weeks
Trial: 11349793
Drug: Local pulsated
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local pulsated pressure treatment
Trial: 10443310
Drug: Anti-GPIIb/IIIa molecules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-GPIIb/IIIa molecules
Trial: 10443310
Drug: Classical anti-aggregant
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical anti-aggregant drugs
Trial: 2085099
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein formula (1.1 g/100 ml)
Trial: 2085099
Drug: Conventional protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional protein formula (1.5 g/100 ml)
Trial: 377971
Drug: Cefazolin, 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin, 1.0 gm administered intramuscularly and cephalothin, 2.0 gm administered intravenously at 6, 12, and 24 hours postoperatively
Trial: 27046159
Drug: Continued thienopyridine
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued thienopyridine and aspirin after 12 months
Trial: 27046159
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and aspirin after 12 months
Trial: 6863579
Drug: Amiloride-hydrochlorothiazide 5/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride-hydrochlorothiazide 5/50 mg/day
Trial: 6863579
Drug: Timolol 20
RxNorm normalized name: timolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 20 mg/day
Trial: 6863579
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of timolol with hydrochlorothiazide
Trial: 6863579
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of timolol with amiloride-hydrochlorothiazide
Trial: 28986164
Drug: Rosiglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone treatment in T2D subjects
Trial: 28986164
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment in T2D subjects
Trial: 28986164
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (T2D subjects before treatment)
Trial: 19629848
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (using plain glasses)
Trial: 24139829
Drug: Sublingual allergen
RxNorm normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual allergen immunotherapy (SLIT)
Trial: 24139829
Drug: Subcutaneous allergen
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous allergen immunotherapy (SCIT)
Trial: 15855490
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine (ddI) in addition to current combination therapy for 4 weeks
Trial: 10918432
Drug: Oral granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral granisetron (2 mg, 1 h before first daily fraction of radiation)
Trial: 10918432
Drug: Oral ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ondansetron (8 mg, 1.5 h prior to each fraction of TBI)
Trial: 10918432
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control group (no 5-HT3-receptor antagonist)
Trial: 6743606
Drug: External cephalic
RxNorm normalized name: Cephaelis ipecacuanha preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External cephalic version under tocolysis with intravenous ritodrine
Trial: 31568714
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of XEN1101
Trial: 24993981
Drug: High-ceiling sulphonamide
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-ceiling sulphonamide diuretics
Trial: 24993981
Drug: Medication acting
RxNorm normalized name: sodium fluoride Mouthwash [ACT Fluoride Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication acting via the renin-angiotensin system
Trial: 24993981
Drug: Non-selective β-blockers
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective β-blockers
Trial: 15793108
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of 1 g every 8 h for 24 h
Trial: 15793108
Drug: 3-h infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-h infusion of 1 g every 8 h for 24 h
Trial: 15793108
Drug: 3-h infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-h infusion of 2 g every 8 h for 24 h
Trial: 11789238
Drug: Shenmai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai injection (intravenous for 7 days)
Trial: 11789238
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Shenmai injection)
Trial: 23943316
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine (DFO) at 62 mg/kg/day (up to a maximum daily dose of 6000 mg/day)
Trial: 21428978
Drug: Cortexolone 17α-propionate
RxNorm normalized name: Cortexolone 17α-propionate
DrugBank: Clascoterone (DB12499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cortexolone 17α-propionate 1% cream
Trial: 21428978
Drug: Tretinoin 0·05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin 0·05% cream
Trial: 15017644
Drug: Collaborative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative treatment (gastroenterologist and psychologist working together)
Trial: 15017644
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment directed at gastrointestinal function
Trial: 9351621
Drug: Budesonide dry
RxNorm normalized name: budesonide Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide dry powder, 800 microg twice daily, delivered from a Turbuhaler
Trial: 21403595
Drug: Low-intensity whole
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity whole body vibration (15 mins, 30 Hz, 0.3 g)
Trial: 21403595
Drug: Higher intensity
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher intensity whole body vibration (2 × 3 mins, 12.5 Hz, 1 g)
Trial: 18602742
Drug: Adjuvant radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiation treatment (ART) with 60 Gray (Gy)
Trial: 18602742
Drug: Adjuvant radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiation treatment (ART) with 60-64 Gy
Trial: 18602742
Drug: Adjuvant radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiation treatment (ART)
Trial: 16645533
Drug: Nomegestrol acetate
RxNorm normalized name: nomegestrol acetate
DrugBank: Nomegestrol acetate (DB13981)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Nomegestrol acetate (NOMAc; 5 mg/day for 10 days x month for 12 months) plus calcium (1 g/day)
Trial: 12819322
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitor (ramipril)
Trial: 12819322
Drug: Dihydropyridine calcium
RxNorm normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydropyridine calcium channel blocker (amlodipine)
Trial: 8795307
Drug: Systemic infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic infusion via the brachial vein (Group S)
Trial: 8795307
Drug: Ipsipedal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipsipedal infusion via the dorsalis pedis vein (Group IP)
Trial: 3217807
Drug: Vindesine (VDS)
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vindesine (VDS) 4 mg/m2 IV weekly X 8, then every second week
Trial: 3217807
Drug: Lomustine (CCNU)
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lomustine (CCNU) 70 mg/m2 orally, cyclophosphamide (CTX) 1000 mg/m2 IV every 4 weeks, methotrexate (MTX) 20 mg/m2 orally days 15 and 18 of each course
Trial: 3217807
Drug: CCNU +
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCNU + CTX + MTX + VDS (lower doses: CCNU 50 mg/m2, CTX 750 mg/m2, VDS 2 mg/m2)
Trial: 29875101
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day quizartinib
Trial: 29875101
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day quizartinib
Trial: 26150601
Drug: SB4 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB4 (50 mg subcutaneous weekly)
Trial: 26150601
Drug: ETN (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETN (50 mg subcutaneous weekly)
Trial: 26776356
Drug: Fibrin sealant
RxNorm normalized name: FIBRIN SEALANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin sealant patch (FSP; TachoSil)
Trial: 21216835
Drug: Tacrolimus monotherapy
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus monotherapy (MONO)
Trial: 17919618
Drug: Tacrolimus combination
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus combination therapy (COMBO)
Trial: 9764968
Drug: L-NMMA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (4 mg kg(‐1) h(‐1) continuous infusion with a front loaded bolus of 4 mg kg(‐1))
Trial: 2238184
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg bendrofluazide
Trial: 2238184
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg bendrofluazide
Trial: 2238184
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg bendrofluazide
Trial: 2238184
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg bendrofluazide
Trial: 2238184
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bendrofluazide
Trial: 360764
Drug: Oral norephedrine
RxNorm normalized name: Norephedrine
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral norephedrine
Trial: 26363720
Drug: Lurasidone 20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 20-60 mg or 80-120 mg
Trial: 26363720
Drug: Lurasidone (continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (continuation treatment)
Trial: 24108252
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine (0-80 mg)
Trial: 24108252
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine (doses >40 mg)
Trial: 21382516
Drug: Community Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community Care (CC) - 6 month SDT-based intervention
Trial: 21382516
Drug: Harm Reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harm Reduction (HR) - Extended need support with medication recommendation
Trial: 18974068
Drug: Activator-headgear appliance
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activator-headgear appliance for at least 9 months followed by fixed appliance therapy
Trial: 18974068
Drug: Minor orthodontic
RxNorm normalized name: Vinca minor extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minor orthodontic treatment (control group)
Trial: 16724576
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg vardenafil plus 0.5 g/kg ethanol
Trial: 14606098
Drug: High-dose Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Vitamin C (10 g/day) intravenously for 5 days
Trial: 14606098
Drug: Low-dose Vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Vitamin C (1 g/day) intravenously for 5 days
Trial: 2024983
Drug: 0.05% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% tretinoin therapy
Trial: 25041339
Drug: basiliximab +
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: basiliximab + belatacept high dose (HD) + mycophenolate mofetil (MMF)
Trial: 25041339
Drug: belatacept low
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: belatacept low dose (LD) + MMF
Trial: 22297244
Drug: Everolimus 10mg
RxNorm normalized name: EVEROLIMUS 10MG TAB
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 10mg once daily (n=277)
Trial: 17372025
Drug: Grass pollen
RxNorm normalized name: grass pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass pollen immunotherapy (Phleum pratense)
Trial: 16279148
Drug: Pravastatin (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (specific dosage and duration not mentioned)
Trial: 10206118
Drug: MDT +
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MDT + 10 daily doses of 2 x 10(6) IU of recombinant human IFN-gamma/m2 followed by 10 daily doses of 10(7) IU IFN-gamma/m2
Trial: 7540413
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody B724
Trial: 7540413
Drug: Control ELISAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control ELISAs using polyclonal antibodies
Trial: 2230890
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (TIOS II)
Trial: 2230890
Drug: Percentage of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percentage of tumor necrosis induced by preoperative chemotherapy
Trial: 7150174
Drug: Benactyzine hydrochloride
RxNorm normalized name: benactyzine hydrochloride
DrugBank: Benactyzine (DB09023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benactyzine hydrochloride (4.14 mg/70 kg body weight)
Trial: 18663319
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (Genotropin) treatment at a median dose of 0.03 mg/kg/day for a median duration of 10.2 years (range 6.9-11.5)
Trial: 10608399
Drug: MultiHance (gadobenate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MultiHance (gadobenate dimeglumine, Gd‐BOPTA) administered at a dosage of 0.05 mmol/kg during the dynamic phase of contrast enhancement.
Trial: 8719517
Drug: Engerix-B (EB)
RxNorm normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix-B (EB) 20 micrograms administered IM at 0, 1, 2, and 12 months
Trial: 8719517
Drug: Recombivax HB
RxNorm normalized name: Recombivax HB
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombivax HB (RHB) 10 micrograms administered IM at 0, 1, and 6 months
Trial: 1837245
Drug: Niaprazine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niaprazine (1 mg/kg body weight)
Trial: 30417225
Drug: 14-day treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day treatment with 10% carbamide peroxide gel applied for 2 hours a day
Trial: 30417225
Drug: 21-day treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 21-day treatment with 10% carbamide peroxide gel applied for 2 hours a day
Trial: 23127291
Drug: Intranasal azelastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal azelastine (AZE; 137 μg/spray)
Trial: 23127291
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone propionate (FP; 50 μg/spray)
Trial: 15020607
Drug: Trastuzumab alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab alone or combined with palliative radiotherapy or hormonal therapy
Trial: 11842886
Drug: Phosphatidylserine (PS)
RxNorm normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylserine (PS) supplementation 300 mg daily for one month
Trial: 3058016
Drug: HPA-23 (ammonium-21-tungsto-9-antimoniate)
RxNorm normalized name: ammonium chloride / antimony potassium tartrate / ipecac
DrugBank: HPA-23 (DB17739)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPA-23 (ammonium-21-tungsto-9-antimoniate) at 0.25, 0.5, 1.0, or 2.0 mg/kg intravenously 5 days per week for 8 weeks
Trial: 21982727
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (three times daily)
Trial: 18775597
Drug: Intravaginal metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal metronidazole (2x 1000 mg pessaries 24h apart)
Trial: 18775597
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole (1 x 2000 mg tablets)
Trial: 12872393
Drug: CT positioning
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT positioning scalp circum-needling (SCN) combined with Chinese herbal medicine (Fuyuan mixture)
Trial: 1947469
Drug: High-dose cytosine
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytosine arabinoside combined with dexamethasone and cisplatinum
Trial: 1947469
Drug: Low-dose cytosine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytosine arabinoside combined with dexamethasone and cisplatinum
Trial: 31389731
Drug: Cyclosporin 4
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin 4 mg/kg/d for 3 months
Trial: 27193374
Drug: Allergen-specific immunotherapy
RxNorm normalized name: Pacific halibut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen-specific immunotherapy (ASIT)
Trial: 25037883
Drug: Subcutaneous growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous growth hormone injection (3 mg/24 h) during exercise (1 hour bicycling with 50 W load)
Trial: 25037883
Drug: Subcutaneous growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous growth hormone injection (3 mg/24 h) during supine rest
Trial: 25037883
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous growth hormone infusion (3 mg/24 h)
Trial: 16804691
Drug: Low alcohol
RxNorm normalized name: Low alcohol beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low alcohol dose (two to three drinks equivalent)
Trial: 16804691
Drug: High alcohol
RxNorm normalized name: High alcohol lager
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High alcohol dose (four to five drinks equivalent)
Trial: 10714423
Drug: Inhaled glucocorticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticosteroids (IGC), 250 microg of fluticasone propionate (FP) twice a day for 8 weeks
Trial: 10714423
Drug: Inhaled glucocorticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticosteroids (IGC)